Meeting Banner
Abstract #5427

MR-HIFU mild hyperthermia for recurrent rectal cancer: updated results from a phase I clinical trial

William Chu1, Robert M Staruch2, Samuel Pichardo3,4, Yuexi Huang5, Merrylee McGuffin1, Ruby Endre5, Gregory Czarnota6, and Kullervo Hynynen5

1Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, 2Clinical Sites Research Program, Philips Research, Cambridge, MA, United States, 3Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada, 4Electrical Engineering, Lakehead University, Thunder Bay, ON, Canada, 5Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada, 6Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

We present the updated results of our phase I trial that delivers mild hyperthermia using magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) combined with radiation and chemotherapy in the treatment of locally recurrent rectal cancer. Participation in the study is based on careful consideration of patient and tumor factors. MR-HIFU mild hyperthermia was delivered in three sessions during a 17-day regimen. MR-HIFU mild hyperthermia was successfully delivered and the procedure was well tolerated. No adverse effects have been reported following the combined treatment to date.

This abstract and the presentation materials are available to members only; a login is required.

Join Here